Paraquat Parkinson’s Lawsuit

The Science of Paraquat Neurotoxicity

The neurotoxic mechanism of paraquat has been extensively studied in both animal models and in vitro cellular systems. Paraquat’s chemical structure is remarkably similar to MPP+, the active metabolite of MPTP — a synthetic compound famously discovered to cause rapid-onset Parkinsonism in drug users in the 1980s. This structural similarity is not coincidental: both compounds target the same cellular machinery in dopaminergic neurons.

When paraquat enters the body through inhalation, dermal absorption, or ingestion, it crosses the blood-brain barrier via amino acid and polyamine transport systems. Once in the brain, paraquat is taken up by dopaminergic neurons in the substantia nigra, where it undergoes redox cycling — a process in which the molecule is repeatedly reduced and re-oxidized, generating massive quantities of superoxide radicals and other reactive oxygen species with each cycle. This oxidative barrage overwhelms the cell’s natural antioxidant defenses, particularly in dopaminergic neurons, which are already under elevated oxidative stress due to dopamine metabolism.

The oxidative stress caused by paraquat directly inhibits mitochondrial complex I, the first enzyme in the electron transport chain. Complex I inhibition disrupts cellular energy production and triggers a self-amplifying cycle of mitochondrial dysfunction and ROS generation. The result is selective death of dopaminergic neurons through both apoptotic (programmed) and necrotic cell death pathways. Additionally, paraquat promotes the aggregation of alpha-synuclein, a protein that forms insoluble fibrillar inclusions known as Lewy bodies. Lewy bodies are the defining pathological feature of Parkinson’s disease, and their presence in paraquat-exposed brains provides direct mechanistic evidence linking the herbicide to the disease.

What Syngenta and ICI Knew

Internal corporate documents obtained through litigation discovery reveal a decades-long pattern of knowledge and suppression. Imperial Chemical Industries (ICI), the original manufacturer of paraquat and corporate predecessor of Syngenta, conducted internal studies as early as 1958 that identified neurotoxic properties of the compound. In 1966, ICI researchers confirmed that paraquat enters the brain in mice, raising direct questions about potential neurological harm in humans.

The most damning evidence comes from the work of Dr. Louise Marks, an ICI/Zeneca scientist whose studies in the 1990s documented cell loss in the substantia nigra of animals exposed to paraquat. These results were consistent with the mechanism that would later be established in independent academic research. However, instead of publishing these findings or reporting them to regulators, ICI/Zeneca suppressed the research. The results were not included in submissions to the EPA or other regulatory bodies.

In 2003, Syngenta developed what internal documents describe as a "Scientific Influencing Strategy" — a coordinated effort to selectively fund, publish, and promote research that minimized the paraquat-Parkinson’s link while suppressing or discrediting research that supported it. Syngenta specifically targeted Dr. Deborah Cory-Slechta, a leading neurotoxicologist whose independent research demonstrated paraquat’s neurotoxicity, working behind the scenes to keep her off EPA advisory panels. The company hired v-Fluence, a reputation management firm, to monitor and influence the scientific discourse around paraquat.

In 2023, Dr. Ray Dorsey and colleagues published a landmark paper documenting what they termed "agnotology" — the deliberate production of ignorance — by Syngenta regarding the paraquat-Parkinson’s connection. The paper systematically catalogued Syngenta’s efforts to manufacture doubt about the scientific evidence, drawing explicit parallels to the tobacco industry’s decades-long campaign to deny the link between smoking and cancer.

The Future of Paraquat Litigation

MDL 3004 represents one of the most significant toxic tort litigations in the United States. With approximately 5,000 cases pending before Judge Nancy J. Rosenstengel in the Southern District of Illinois, the litigation has reached a critical juncture. The initial $187.5 million settlement by Syngenta in June 2021, followed by the MDL framework settlement agreement in April 2025, signals the defendants’ recognition of significant liability exposure.

The litigation has been shaped by the Daubert ruling in April 2024, in which Judge Rosenstengel excluded the testimony of Dr. Martin Wells, a statistician whose work was central to some plaintiffs’ causation arguments. Four bellwether cases were dismissed as a result. However, the broader scientific evidence supporting the paraquat-Parkinson’s link — including the FAME study, multiple meta-analyses, and mechanistic research — remains available to plaintiffs through other expert witnesses. The Mertens bellwether case settled on the eve of trial in January 2026, and two Philadelphia state court cases settled in July and October 2025, demonstrating continued settlement momentum.

The trajectory of paraquat litigation mirrors other successful toxic tort campaigns against manufacturers who knew their products caused harm and chose profit over public safety. The combination of strong scientific evidence, damning internal corporate documents, and a sympathetic plaintiff class of farmworkers and rural residents creates substantial pressure for comprehensive resolution.